Objective: The purpose of this study was to determine if treatment of pregnant women with Chlamydia trachomatis infection would lower the incidence of preterm delivery and/or low birth weight.
trachomatis in the placebo group, these data do not provide unequivocal evidence that erythromycin use in all C. trachomatis-infected women prevents low birth weight. Infect. Dis. Obstet. Gynecol. 5:10-17, 1997. (C) 1997Wiley-Liss, Inc.
KEY WORDS chlamydial infection; premature delivery; low birth weight he prevalence of Chlamydia trachomatis varies widely depending upon the population, with 5-15% of pregnant women being infected. [1] [2] [3] During pregnancy, C. trachomatis is isolated 4-8 times more frequently than Neisseria gonorrhoeae, z,4,s C.
trachomatis is particularly common among adolescents and individuals from low socioeconomic groups, 6, 7 and it has been associated with adverse pregnancy outcomes in most, but not all, reports. 1,z,4,6,8, 9 Treatment of C. trachomatis in pregnancy has been associated with improved pregnancy outcome. In one study, the rate of abnormal pregnancy outcome was significantly lower in women with C. trachomatis who were treated with erythromycin over a 20 month study period compared to the rate in untreated women examined during the 16 month interval preceding the study period. 1 Furthermore, women infected with C. trachomatis who were treated had the same frequency of abnormal outcome as did uninfected women. 1 In another study, fewer abnormal pregnancy outcomes occurred among C. trachomatis-positivc women who were effectively treated than among those who remained culture positive. 1 Neither of these studies used a randomized or blinded treatment protocol nor did they account for other bacteria or obstetrical factors associated with poor pregnancy outcome.
We report the results of a randomized placebocontrolled double-blinded trial of erythromycin treatment of C. trachomatis infection during pregnancy. Our study was able to adjust for the influence of demographic, sexual, and obstetrical factors as well as the presence of other potentially pathogenic organisms isolated from the lower genital tract. Eligible women who agreed to participate in the clinical trial entered a week placebo run-in. 6 Those who took less than two-thirds of the allotted placebo pills during the run-in, who did not return to the clinic or refused further participation were not randomized. Patients who successfully completed the run-in, had none of the exclusion criteria, and were <30 weeks gestation were randomized as described previously. 3 The randomization scheme stratified women by study site and microorganism combination to allow for subgroupspecific analyses. Participants were treated with either erythromycin base (333 mg) or identicalappearing placebo tablets 3 times daily from blister packs containing 21 pills each. The erythromycin and placebo were supplied by the Upjohn Company (Kalamazoo, MI).
SUBJECTS AND METHODS

Study Design
As a result of concerns that a daily dose of 2 g of erythromycin would be poorly tolerated over 6 weeks, the lower g dose was chosen. Earlier reports suggested that a g daily dose for 6 weeks in the third trimester decreased the rate of low birth weight infants among women colonized with genital mycoplasmas. 7 Previous experience of the investigators suggested that 500 mg erythromycin taken twice daily for 14 days effectively treated endocervical C. trachomatis in pregnant women (Martin and Two methods were used for quality control of (7. trachomatis cultures. Each study site in turn sent 5 "unknowns" that included both positive and negative specimens to the other centers. In addition, a random sample of women had duplicate C. trachomatis specimens obtained and submitted to the laboratories for culture. Different study numbers were assigned to blind laboratory personnel to the duplicate specimens.
Definitions
Gestational age at study entry was estimated from the last menstrual period, results of the first pelvic examination, onset of fetal heart tone, and ultrasound data when available. Gestational age at delivery was calculated from the entry estimate and the time to delivery. All women had pertinent pregnancy, labor, and delivery information collected including the use of non-trial antibiotics. Endocervical C. trachomatis cultures obtained mid-study, while women were still receiving the study drug, remained positive in 20% of erythromycin-treated and 63% of placebo-treated women (P < 0.001). C. trachomatis was recovered from 8 (14%) of 56 erythromycin-treated women who took two-thirds or more of their pills compared to 7 (33%) of 19 women taking less than two-thirds of their erythromycin (P 0.03).
Because of the unexpectedly high clearance of C. trachomatis in the placebo group (37%), the data were analyzed separately by study site (Table 3) . The interim recovery rates were low (24-25%) 
